Clinical Trial Update: ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating ZEN-3694 in combination with enzalutamide and pembrolizumab for metastatic castration-resistant prostate cancer; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer
• Small Cell Carcinoma of the Prostate

Drugs mentioned

• Enzalutamide (enzalutamide)
• Pembrolizumab (pembrolizumab)
• ZEN-3694

Snippet

Sponsor: Rahul Aggarwal | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING